Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren-GETUG AFU 26 trial.

被引：0
|
作者：
Colomba, Emeline [1 ]
Flippot, Ronan [2 ]
Dalban, Cecile [3 ]
Negrier, Sylvie [4 ]
Chevreau, Christine [5 ]
Gravis, Gwenaelle [6 ]
Oudard, Stephane [7 ]
Laguerre, Brigitte [8 ]
Barthelemy, Philippe [9 ]
Goupil, Marine Gross [10 ]
Geoffrois, Lionnel [11 ]
Rolland, Frederic [12 ]
Thiery-Vuillemin, Antoine [13 ]
Joly, Florence [14 ]
Ladoire, Sylvain [15 ]
Tantot, Florence [16 ]
Escudier, Bernard [17 ]
Albiges, Laurence [18 ]
机构：
[1] Paris Saclay Univ, Gustave Roussy Canc Campus, Villejuif, France
[2] Gustave Roussy, Dept Med Oncol, Villejuif, France
[3] Ctr Leon Berard, Lyon, France
[4] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[5] IUCT Oncopole Inst Claudius Regaud, Toulouse, France
[6] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France
[7] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Oncol, Paris, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Inst Cancerol Strasbourg Europe, Strasbourg, France
[10] CHU Bordeaux, Bordeaux, France
[11] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[12] Inst Cancerol Ouest, Dept Med Oncol, St Herblain, France
[13] Univ Hosp Jean Minjoz, Besancon, France
[14] Ctr Francois Baclesse, Dept Med Oncol, Caen, France
[15] Georges Francois Leclerc Canc Ctr, Dijon, France
[16] UNICANCER, Le Kremlin Bicetre, France
[17] Gustave Roussy, Villejuif, France
[18] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.359
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
359
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC): A GION trial.
    Porta, Camillo
    Ferrari, Vittorio D.
    Zucali, Paolo Andrea
    Fornarini, Giuseppe
    Bernardo, Antonio
    Falconeri, Andrea
    Ferrari, Alessandra
    Santarossa, Sandra
    Pappagallo, Giovanni L.
    Bearz, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.
    Zhou, Ai-Ping
    Bai, Yuxian
    Song, Van
    Li, Hangzhong
    Xie, Xiaodong
    Ren, Xiu-Bao
    Ye, Dingwei
    Liu, Jiyan
    Luo, Hong
    Bai, Xianzhong
    Qin, Shukui
    Fu, Cheng
    Wang, Jinwan
    Ma, Jianhui
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes
    Choueiri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard
    McDermott, David F.
    Kluger, Harriet M.
    Stadler, Walter Michael
    Perez-Gracia, Jose Luis
    McNeel, Douglas G.
    Curti, Brendan D.
    Harrison, Michael Roger
    Plimack, Elizabeth R.
    Appleman, Leonard Joseph
    Fong, Lawrence
    Drake, Charles G.
    Young, Tina C.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Simon, Jason S.
    Walker, Dana
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Zibelman, Matthew R.
    Geynisman, Daniel M.
    Molina, Ana M.
    Malizzia, Lois
    Devarajan, Karthik
    Luong, Diana
    Sullivan, Elizabeth
    Carducci, Michael Anthony
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES
    Choueri, Toni K.
    Fishman, Mayer N.
    Escudier, Bernard
    McDermott, David F.
    Kluger, Harriet
    Stadler, Walter M.
    Perez-Gracia, Jose L.
    McNeel, Douglas
    Curti, Brendan
    Harrison, Michael R.
    Plimack, Elizabeth R.
    Appleman, Leonard
    Fong, Lawrence
    Drake, Charles G.
    Young, Tina C.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Simon, Jason S.
    Walker, Dana
    Sznol, Mario
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 119 - 119
  • [36] Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
    Escudier, Bernard
    Barthelemy, Philippe
    Ravaud, Alain
    Negrier, Sylvie
    Needle, Michael N.
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [37] NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N)
    Vano, Y.
    Rioux-Leclercq, N.
    Dalban, C.
    Sautes-Fridman, C.
    Bougouin, A.
    Chaput, N.
    Chouaib, S.
    Beuselinck, B.
    Chevreau, C. M.
    Gross-Goupil, M.
    Negrier, S.
    Laguerre, B.
    Borchiellini, D.
    Colina-Moreno, I.
    Fridman, W. H.
    Chabaud, S.
    Tantot, F.
    Monteiro, J. Barros
    Escudier, B.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 360 - +
  • [38] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC).
    Amato, R. J.
    Misellati, A.
    Khan, M.
    Chiang, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [40] Activity of second line axitinib in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib: Results from SAX Italian real world trial.
    Rossetti, Sabrina
    Romano, Francesco Jacopo
    D'Aniello, Carmine
    Cavaliere, Carla
    Pisconti, Salvatore
    Iovane, Gelsomina
    Berretta, Massimiliano
    Marchetti, Paolo
    Crisp, Anna
    Piscitelli, Raffaele
    Muto, Paolo
    Maiolino, Piera
    Perdona, Sisto
    Botti, Gerardo
    Facchini, Gaetano
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345